ESPERION THERAPEUTICS INC (ESPR)

US29664W1053 - Common Stock

2.06  +0.02 (+0.98%)

After market: 2.06 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
78.4M
-65.54%		75.5M
-3.70%		116.334M
54.08%		270.44M
132.47%
EBITDA
YoY % growth
-212.79M
-76.08%		-179M
15.88%		-155.399M
13.18%		1.921M
101.24%		N/AN/A
EBIT
YoY % growth
-213.4M
-75.78%		-179.5M
15.89%		-155.563M
13.34%		-16.81M
89.19%
Operating Margin
-272.19%-237.75%-133.72%-6.22%
EPS
YoY % growth
-9.56
-74.45%		-3.55
62.87%		-2.12
40.28%		-0.41
80.56%		N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.05
106.36%
Revenue
Q2Q % growth		86.199M
254.73%
EBITDA
Q2Q % growth		36.74MN/AN/AN/AN/A
EBIT
Q2Q % growth		32.305M
166.47%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.50
34.21%		-0.49-0.01-1.60%
Q3 2023
Q2Q % growth		 -0.37
54.32%		-0.440.0716.08%
Q2 2023
Q2Q % growth		 -0.46
56.19%		-0.620.1626.23%
Q1 2023
Q2Q % growth		 -0.79
15.05%		-0.67-0.12-18.72%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 32.25M
71.54%		29.271M2.979M10.18%
Q3 2023
Q2Q % growth		 34M
78.95%		30.175M3.825M12.68%
Q2 2023
Q2Q % growth		 25.8M
37.23%		25.13M670K2.67%
Q1 2023
Q2Q % growth		 24.3M
29.26%		22.452M1.848M8.23%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 170.36% -2254.67% -18.91%
Revenue0% 1.94% -15.46% -12.09%